Celanese's Earnings Call Flags Shifting Timelines for Raw Material Impact and Restructuring Benefits

<<>>

Date of Call: Aug 5, 2026

Guidance:

• Q3 2026 EPS guidance of $1.35 to $1.75 per share.
• Full-year 2026 free cash flow guidance of $700M to $800M, considered a baseline sustainable level.
• Expect 80-100M of cost reductions to take effect in 2027 to offset business moderation.
• Targeting ~$500M in divestitures by end of 2027, about halfway achieved after Micromax transaction.
• Expect continued moderation in acetyl supply chain benefits in H2 2026 as initially guided.

Business Commentary:

Supply Chain and Pricing Strategy:

• Selenese's acetyl chain showed strong resiliency and flexibility, with Q2 benefiting from strategic actions to ensure reliable supply, particularly in Europe.
• The company's pricing strategy and ability to manage supply chain disruptions contributed to better-than-expected results in Q2.

Engineering Materials (EM) Segment:

• The EM segment's engineered materials showed a focus on high-value applications like electronics and medical, which accounted for 10-15% of revenue and 20% of contribution margin.
• The strategy to align with key end markets and penetrate specific sub-segments is aimed at sustainable long-term growth.

Free Cash Flow and Working Capital:

• Selenese maintained a confident outlook on free cash flow, projecting $700 to $800 million for 2026, despite a $300 million use of cash in working capital year-to-date.
• The guidance is supported by earnings growth and expected benefits from structural inventory reduction and lower restructuring costs.

Divestitures and Portfolio Strategy:

• The company is committed to reaching a $1 billion divestiture target by the end of 2027, having completed $500 million so far.
• Ongoing efforts include a portfolio of various-sized items to enhance focus and efficiency, with plans to announce at least one deal by year-end.

Capacity and Rationalization Efforts:

• Selenese continues to evaluate additional opportunities for plant rationalization, with potential benefits expected to be smaller and more focused on efficiency improvements.
• The strategic focus remains on optimizing the global footprint and enhancing specialty compounding leadership.

Sentiment Analysis:

Overall Tone: Positive

• Management highlighted 'strong resiliency and flexibility' and 'really nice job for them offsetting' significant headwinds. They expressed confidence in free cash flow guidance and stated 'we feel like our ability to generate cash here at Celanese is strong.' The tone was optimistic about growth in engineered materials sub-segments and cost reduction actions.

Q&A:

• Question from Patrick Cunningham (Citi): Could you talk through the normalization of some of the supply-related opportunities in the acetyl chain? How would you characterize the operating environment, Western Hemisphere versus Eastern Hemisphere? And what is driving the upward movement in Asia spreads?
  Response: Moderation in H2 is as expected, with Q2 benefiting slightly more from pre-buying. Asia spreads were short-lived, and margins are back to pre-war levels; Western Hemisphere margins remain elevated but not at pre-war peaks.

• Question from Gansham Punjabi (Baird): How have things changed relative to the pre-war baseline for the acetyl chain across product lines and geographies?
  Response: Western Hemisphere has consistently generated 80%+ profitability for 12 of the last 15 years; Asia's margin spike was temporary, and the business is now back to pre-war levels. The team is pivoting to sell more downstream derivatives for differentiation.

• Question from Jeff Sikakis (J.P. Morgan): Acetyl chain volumes were flat YOY in the quarter. Why didn't they grow given available capacity and competitor outages?
  Response: Offset by destocking in acetate tow and higher sequential emulsion volumes in Q2 2026 compared to Q2 2025.

• Question from David Begleiter (Deutsche Bank): On EM, what is the price/cost outlook for Q2 and the back half of the year?
  Response: Pricing actions in H2 Q2 positioned the company to offset a chunk of raw material inflation in Q3, though some compression is expected as raw material costs flow through.

• Question from Kevin McCarthy (Vertical Research Partners): What is the outlook for acetate tow in H2, and what is the impact of the Linnokin closure? Also, any update on divestitures and joint ventures?
  Response: Destocking in tow is moderating; Linnokin closure accelerating will drive higher inventory absorption in H2 but benefits 2027 costs. Committed to $500M divestiture target by end of 2027, with at least one deal expected this year.

• Question from Frank Mitch (Fermi & Research): How much visibility do you have on order books for the balance of Q3? And what were the turnaround expenses in Q2 and expectations for Q3/Q4?
  Response: Visibility is decent through August, with September typically strongest. Turnaround expenses were ~$15M in EM for Q2; the balance of the year looks clean.

• Question from Vincent Andrews (Morgan Stanley): What are the plans for the Frankfurt asset? Is it part of maintaining share gains?
  Response: Frankfurt was restarted quickly; it will operate for the balance of the year depending on demand and supply dynamics.

• Question from Hasan Ahmed (Alembic Global): Could you expand on the lag effect of raw material cost impacts and pricing benefits? Also, when will restructuring benefits be seen?
  Response: Acetyl pricing lag is minimal; EM raw material lag is now flowing through in Q3. ~1/3 of Linnokin savings and ~1/2 of nylon restructuring will be realized in 2026, with the rest in 2027.

• Question from Matthew DeYo (Bank of America): How does the GLP-1 pill impact the $500M TAM? And why has auto growth decelerated relative to builds?
  Response: The TAM outlook is conservative and includes GLP-1 pills; focus has shifted from volume to value and mix enrichment in automotive, with growth from non-auto segments being more important.

• Question from Abigail Ebert (Wells Fargo): Are there other potential candidates for rationalization beyond recent closures?
  Response: Additional smaller opportunities (5-10M per site) exist, but focus is shifting to supply chain efficiency and cost improvements post-footprint actions.

• Question from Lawrence Alexander (Jefferies): What is the net impact of divestitures, inventory adjustments, and absorption on the comparable 2027 base?
  Response: EM faces ~$90M of headwinds from divestiture absorption and lost equity earnings but is expected to grow EBIT double-digits. AC has an extra $20M absorption hit in H2. Cost reductions and free cash flow will help offset these.

• Question from Josh Spector (UBS): SG&A and other activities lines are up ~$30M YTD. How do you expect them to trend in H2 and square with functional cost savings?
  Response: The increase in 'other activities' is due to timing of compensation accruals; expect ~$75M per quarter going forward. SG&A increase is related, with base to be adjusted accordingly.

Contradiction Point 1

Q3 Earnings Guidance Drivers

Key drivers for Q3 guidance range are reiterated but with different emphasis.

What is your primary question for the management team? - David Begleiter (Deutsche Bank)

2026Q2: Key priorities to hit the higher end of the Q3 range are: 1) maintaining pricing to offset raw material inflation, 2) providing reliability of supply, and 3) focusing on productivity and cost reduction. Driving mix improvement in EM is also a factor. - Scott Richardson(CEO)

What factors determine the top versus the lower end of your Q3 guidance range? - David Begleiter (Deutsche Bank)

2026Q2: The focus is on driving productivity and cost reduction, and continuing the multi-quarter trajectory of mix improvement in EM. These are critical to achieving the higher end of the guidance range. - Scott Richardson(CEO)

Contradiction Point 2

Engineered Materials (EM) Volume Growth and Auto Sector Exposure

Characterization of EM volume growth and auto sector performance appears inconsistent.

Jeff Sikakis (J.P. Morgan) - Jeff Sikakis (J.P. Morgan)

2026Q2: Auto volumes moved with builds, down year-over-year. Excluding the divestiture, EM volumes were flattish year-over-year, meaning non-auto volumes were up. - Scott Richardson(CEO)

What were the growth rates for the auto and non-auto sectors in engineered materials, exclusive of the divestiture, in the quarter? - Matthew DeYo (Bank of America)

2026Q2: The focus has shifted from volume to value in EM, especially in automotive. With polymer capacity increasing in China, it's challenging to outgrow standard grade material demand there. The strategy is on share gains and penetration in high-value segments (including non-auto). Growth in drug delivery... is expected to continue. - Scott Richardson(CEO)

Contradiction Point 3

Financial Impact of Divestitures and Restructuring on Comparable 2027 Base

Presentation of headwinds for the comparable 2027 EBIT base is less specific in the latest call.

Lawrence Alexander (Jefferies) - Lawrence Alexander (Jefferies)

2026Q2: For 2026, EM faces headwinds: ~$45M absorption from nylon optimization, ~$35M loss from Micromax divestiture, ~$10M lower equity earnings from Ibn Sina. - Scott Richardson(CEO)

What is the actual comparable base for 2027, and is it significantly different from six in either direction? - Lawrence Alexander (Jefferies)

2026Q2: Engineered Materials faced several headwinds at the start of 2026: ~$45M absorption from nylon optimization, a ~$35M adjusted EBIT loss from the Micromax divestiture, and a ~$10M decline in equity earnings from Ibn Sina. - Chuck Kyrush(CFO)

Contradiction Point 4

Timing of Raw Material Cost Lag Impact on Q3

The quarter when the full impact of raw material cost increases is felt shifts from Q3 to Q2.

What were Hasan Ahmed's key points at Alembic Global's earnings call? - Hasan Ahmed (Alembic Global)

2026Q2: The majority of the positive price benefit was achieved in Q2... The lag effect... is now flowing through in Q3. - Scott Richardson(CEO)

How did the aggressive price hikes in Q2 affect the percentage of longer-duration EM contracts? - Hasan Ahmed (Alembic Global)

2026Q1: We expect the full year impact of higher raw material costs to be felt in Q3. - Scott Richardson(CEO)

Contradiction Point 5

Financial Recognition of Divestiture and Restructuring Benefits

The year in which the majority of restructuring benefits are recognized shifts from 2026 to 2027.

Hasan Ahmed (Alembic Global) - Hasan Ahmed (Alembic Global)

2026Q2: ~$30-$35M of EM footprint benefits and ~$20M of Linnokin benefits will be realized in 2027. For 2026: ~1/3 of Linnokin savings and ~1/2 of nylon restructuring savings will be recognized. - Scott Richardson(CEO)

"When will the $50 million annualized benefit from restructuring/nylon optimization and $20-25 million from Lenarkin start impacting the P&L?" - Hasan Ahmed (Alembic Global)

2026Q1: We expect to recognize the majority of the restructuring benefits in 2026, with the remaining benefits coming in 2027. - Scott Richardson(CEO)

<<>>